Synonym
Clomacran phosphate; SKF14336; SKF-14336; SKF 14336
IUPAC/Chemical Name
9-Acridinepropanamine, 2-chloro-9,10-dihydro-N,N-dimethyl-, phosphate (1:1)
InChi Key
SKKDWRIEPIZVOR-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H21ClN2.H3O4P/c1-21(2)11-5-7-14-15-6-3-4-8-17(15)20-18-10-9-13(19)12-16(14)18;1-5(2,3)4/h3-4,6,8-10,12,14,20H,5,7,11H2,1-2H3;(H3,1,2,3,4)
SMILES Code
CN(C)CCCC1C2=C(C=CC=C2)NC3=CC=C(Cl)C=C13.O=P(O)(O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
398.82
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Simpson GM. Clomacran-Phosphat gegen chronische Schizophrenie [Clomacran- phosphate against schizophrenia]. Munch Med Wochenschr. 1970 Oct 16;42:3. German. PMID: 5536267.
2: Pecknold JC, Ban TA, Lehmann HE, Climan M. Clomacran in the treatment of schizophrenic patients: a comparison of two assessment methods. Int J Clin Pharmacol Biopharm. 1975 Jun;11(4):299-303. PMID: 1099021.
3: Irwin GM, Dodson GJ, Ravin LJ. Encapsulation of clomacran phosphate [2-chloro-9[3-(dimethylamino) propyl]acridan phosphate] I. Effect of flowability of powder blends, lot-to-lot variability, and concentration of active ingredient on weight variation of capsules filled on an automatic capsule-filling machine. J Pharm Sci. 1970 Apr;59(4):547-50. doi: 10.1002/jps.2600590423. PMID: 5440686.
4: Lampe WT 2nd. Adverse effects with clomacran. J Clin Pharmacol J New Drugs. 1970 May-Jun;10(3):171-4. PMID: 5266631.
5: Samara MT, Cao H, Helfer B, Davis JM, Leucht S. Chlorpromazine versus every other antipsychotic for schizophrenia: a systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs. Eur Neuropsychopharmacol. 2014 Jul;24(7):1046-55. doi: 10.1016/j.euroneuro.2014.03.012. Epub 2014 Apr 4. PMID: 24766970.
6: Lampe WT 2nd. A double blind study of clomacran. Curr Ther Res Clin Exp. 1969 May;11(5):300-6. PMID: 4977403.
7: Rickels K, Perloff M, Perez LA, Pereira-Ogan JA, Kelly EA, Hesbacher PT. Clomacran in anxious neurotic outpatients: a controlled study. J Clin Pharmacol New Drugs. 1972 Jan;12(1):46-53. doi: 10.1002/j.1552-4604.1972.tb00035.x. PMID: 4550225.
8: Edwards JG, Simpson GM. A trial of clomacran phosphate (SK&F 14,336) in mania. Curr Ther Res Clin Exp. 1969 Mar;11(3):115-7. PMID: 4976239.
9: Nair KC, Chen CH. Clinical trial of clomacran phosphate (SKF-14336) in chronic psychotic male patients. Curr Ther Res Clin Exp. 1970 Jun;12(6):394-401. PMID: 4987347.
10: Fowler PJ, Zirkle CL, Macko E, Kaiser C, Sarau H, Tedeschi DH. Pharmacological evaluation of clomacran, a new potent psychotropic agent. Arzneimittelforschung. 1977;27(4):866-72. PMID: 17419.
